公开(公告)号：US12226428B2

公开(公告)日：2025-02-18

申请号：US18330293

申请日：2023-06-06

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen ,  Lisbet Kværnø ,  Morten Jørgensen ,  Martin Juhl

IPC: A61K31/706 ,  A61K31/473 ,  A61P25/00 ,  C07D405/12 ,  C07D405/14

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12215144B2

公开(公告)日：2025-02-04

申请号：US18609223

申请日：2024-03-19

Applicant: H. LUNDBECK A/S

Inventor： Roger K. Cady ,  Jeffrey T.L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/4172 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

公开(公告)号：US20240425521A1

公开(公告)日：2024-12-26

申请号：US18679695

申请日：2024-05-31

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Wanwan Yu ,  Thomas Leegaard Andersen ,  Erhad Ascic ,  Michael Baek ,  Gitte Kobberøe Mikkelsen ,  Andreas Michael Arnold ,  Anders Højgaard Hansen ,  Petra Lindovská ,  Henrik Juhani Keränen ,  Ferran Planas Padrós

IPC: C07D498/14 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/429 ,  A61K31/437 ,  A61K31/519 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.

公开(公告)号：US12152029B2

公开(公告)日：2024-11-26

申请号：US18051654

申请日：2022-11-01

Applicant: H. Lundbeck A/S

Inventor： Thomas Vetter ,  Martin Juhl ,  Heidi Lopez De Diego ,  Cheryl A. Grice ,  John J. M. Wiener ,  Daniel J. Buzard ,  Amy Allan ,  Susana Del Rio Gancedo ,  Samuel George Andrew ,  Antonio Cincotti ,  Adam Ross Patterson ,  Richard James Edwards

IPC: C07D471/10

Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12122821B2

公开(公告)日：2024-10-22

申请号：US16510220

申请日：2019-07-12

Applicant: H. LUNDBECK A/S

Inventor： Brian Baker ,  Jeffrey T.L. Smith ,  John Latham

IPC: C07K16/18 ,  A61K39/00 ,  C07K16/26 ,  G01N33/50 ,  G01N33/66

CPC classification number: C07K16/18 ,  G01N33/5038 ,  G01N33/5088 ,  G01N33/66 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/76 ,  G01N2333/5753

Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

公开(公告)号：US20240319203A1

公开(公告)日：2024-09-26

申请号：US18579620

申请日：2022-08-04

Applicant: H. LUNDBECK A/S

Inventor： Anne-Marie JACOBSEN ,  Line Rorbaek OLSEN ,  Frank SCHALK ,  Nico van de MERBEL

IPC: G01N33/68

CPC classification number: G01N33/6848 ,  G01N33/6842 ,  G01N33/6896 ,  G01N2800/2821 ,  G01N2800/52

Abstract: The present invention relates to a method of measuring pS396 Tau in a sample comprising the steps of i-iv, i) Treating a CSF sample from a subject suffering or suspected to be suffering from a Tau pathology with trypsin, ii) Subjecting the sample in step i) to a desphosphorylation agent and subsequently take part of the sample aside for step iv) before proceeding to step iii) with the remaining sample, iii) Subjecting the dephosphorylated sample from step ii) to a second trypsin treatment, iv) Measuring the amount of the Tau peptides (SPVVSGDTSPR) corresponding to Tau residues 396-406 in the samples from step ii) and step iii) using LC-MS.

公开(公告)号：US20240293397A1

公开(公告)日：2024-09-05

申请号：US18483780

申请日：2023-10-10

Applicant: H. Lundbeck A/S

Inventor： Marianne DRAGHEIM ,  Ioana Florea

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: The invention provides new therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]-piperazine and pharmaceutically acceptable salts thereof.

公开(公告)号：US12077794B2

公开(公告)日：2024-09-03

申请号：US16272079

申请日：2019-02-11

Applicant: H. LUNDBECK A/S

Inventor： Gary Lesnicki ,  Mark Young

IPC: C12P21/00 ,  C12N1/16 ,  C12N15/67 ,  C12N15/90

CPC classification number: C12P21/00 ,  C12N1/16 ,  C12N15/67 ,  C12N15/905 ,  C07K2317/14 ,  C12N2523/00

Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.

公开(公告)号：US20240270832A1

公开(公告)日：2024-08-15

申请号：US18609223

申请日：2024-03-19

Applicant: H. LUNDBECK A/S

Inventor： Roger K. Cady ,  Jeffrey T.L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/4172 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K31/4172 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

公开(公告)号：US20240239880A1

公开(公告)日：2024-07-18

申请号：US18609247

申请日：2024-03-19

Applicant: H. LUNDBECK A/S

Inventor： Roger K. Cady ,  Jeffrey T.L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/4172 ,  A61K39/395 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K31/4172 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.